Translate Bio Acquisition, Valuation, Funding & Investors

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

Hypera SA is a specialty and generic drug manufacturing company. The company has a focus on the pharmaceutical segments of the Brazilian market, along with a presence in nonprescription drugs and branded generics. Hypermarcas also possesses a share of generic medicines and prescription products. The company also has a wide sales and distribution structure. The Company's operating segments are Consumer Health, Branded Prescription, Similars e Generics, Skincare and the Non-Retail Market.

Cytovant is a biopharmaceutical company developing cellular therapeutics including modified T-cell receptors and dendritic cell vaccines targeting tumor antigens. The firm advances therapies to enhance immune recognition and destruction of cancer cells in solid and hematologic malignancies.

Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.

Hebei Changshan Biochemical Pharmaceutical Co Ltd is a biotech high-tech enterprise. It is mainly engaged in the research, development, production, and sale of heparin series products. Some of the company's products are Reserpine sodium, Hyaluronic acid, Heparinoid, Heparin sodium, Tinzaparin sodium, Aspirin enteric-coated tablets, and Yihaitang.

Jiangsu Nhwa Pharmaceutical Co Ltd is a drug manufacturer. The company is engaged in the manufacturing of APIs and dosages. The company markets its pharmaceutical products in four main categories: anesthetic drugs, such as midazolam injection and etomidate fat emulsion injection; psychiatric drugs, including risperidone tablets and related products; neurological drugs, such as gabapentin capsules; and bulk pharmaceuticals, including fenofibrate and miconazole nitrate. In addition, the company is also involved in the pharmaceuticals trading business.

Walvax Biotechnology Co Ltd is engaged in research and development, production and sales of vaccine products.

Sinovac Life Sciences is a research-driven biopharma conducting vaccine R&D, production, and commercialization for human infectious diseases. Based in China, it focuses on viral pathogens through clinical trials, process scale-up, and regulatory filings. Operations mirror Sinovac Biotech efforts in formulation stability and large-scale filling for needle-free and traditional delivery systems.

Tasly Pharmaceutical Group Co Ltd is a China-based company engaged in the manufacturing and distribution of pharmaceutical products. Its herbal medicines include Tasly Cerebral Care Granules and Tasly ICP. Its chemical medicines comprise of Ketotifen Fumarate Tablets, Thiamphenicol Capsules, Glucurolactone Tablets and Sulpiride Tablets. Some of the other products offered by the company include PharmceuticalSubstances & API, HerbalExtract, and Concentrated Herbal Granules.

NewLimit is a South San Francisco-headquartered biotechnology company advancing epigenetic reprogramming to extend human healthspan. The firm develops therapies restoring cellular function in aging tissues, targeting diseases like neurodegeneration and cardiovascular conditions. NewLimit's platform integrates machine learning with partial reprogramming techniques to identify optimal rejuvenation protocols.

Livzon Pharmaceutical Group Inc is engaged in China's healthcare sector. As a pharmaceutical manufacturer, the company's portfolio comprises Western pharmaceutical preparations, bulk drugs, traditional Chinese medicines, as well as diagnostic reagents and equipment. Its drug addresses serious conditions such as gastrointestinal, cardiovascular, anti-infectious, antimicrobial, antineoplastic, hemopoietic system, and other conditions. It distributes its products within domestic markets and to overseas markets. It operates in a single reportable segment in the PRC which is pharmaceutical manufacturing.

Jilin Aodong Pharmaceutical Group Co Ltd is engaged in manufacturing of pharmaceuticals. Its products include Anshen Bunao Liquid, Antelope Cough Syrup, Yangxue Yin Oral Liquid, Xinnao Shutong Capsule, Calf Spleen Extract Injection, Xuefu Zhuyu Oral Liquid, and others.

Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.

MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.

Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.

Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

Heyuan Biotechnology is a Chinese provider of gene therapy services, specializing in AAV and lentiviral vector production, CRISPR-based gene editing, and in vivo efficacy testing. Operating from facilities certified under ISO 13485, it supports pharma clients with plasmid design, viral packaging at titers exceeding 10^13 vg/mL, and animal model studies for CNS and oncology targets.